@article{TrebingElMeserySchaeferetal.2014,
  author    = {Trebing, J. and El-Mesery, M. and Sch{\"a}fer, V. and Weisenberger, D. and Siegmund, D. and Silence, K. and Wajant, H.},
  title     = {CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants},
  series = {Cell Death \& Disease},
  volume    = {5},
  journal   = {Cell Death \& Disease},
  doi       = {10.1038/cddis.2013.555},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-120078},
  pages     = {e1035},
  year      = {2014},
  abstract  = {To combine the CD27 stimulation inhibitory effect of blocking CD70 antibodies with an antibody-dependent cellular cytotoxicity (ADCC)-independent, cell death-inducing activity for targeting of CD70-expressing tumors, we evaluated here fusion proteins of the apoptosis-inducing TNF family member TRAIL and a single-chain variable fragment (scFv) derived from a high-affinity llama-derived anti-human CD70 antibody (lαhCD70). A fusion protein of scFv:lαhCD70 with TNC-TRAIL, a stabilized form of TRAIL, showed strongly enhanced apoptosis induction upon CD70 binding and furthermore efficiently interfered with CD70-CD27 interaction. Noteworthy, introduction of recently identified mutations that discriminate between TRAILR1 and TRAILR2 binding into the TRAIL part of scFv:lαhCD70-TNC-TRAIL resulted in TRAIL death receptor-specific fusion proteins with CD70-restricted activity.},
  language  = {en}
}